Xilio Therapeutics (United States)

InstitutionResearch output, impact & collaborations

Xilio Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Xilio Therapeutics (United States)?

ScholarIQrecord summary

Xilio Therapeutics (United States) is a research organisation in Waltham, United States. OpenAlex records 90 works and 8,832 citations for it. 1 researchers list it as their most recent affiliation.

How many works does Xilio Therapeutics (United States) have?

ScholarIQindexed works

Xilio Therapeutics (United States) has 90 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Xilio Therapeutics (United States) →

How many citations does Xilio Therapeutics (United States) have?

ScholarIQcitation count

Xilio Therapeutics (United States) has 8,832 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Xilio Therapeutics (United States) →

How many researchers are at Xilio Therapeutics (United States)?

ScholarIQresearcher count

Xilio Therapeutics (United States) has 1 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Xilio Therapeutics (United States)?

ScholarIQavg h-index

Xilio Therapeutics (United States) has an average h-index of 59 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Xilio Therapeutics (United States)?

ScholarIQror

The ROR for Xilio Therapeutics (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Xilio Therapeutics (United States)?

ScholarIQopenalex

The OpenAlex for Xilio Therapeutics (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Xilio Therapeutics (United States)?

ScholarIQtop researchers by citations

Bruce J. Dezube · Viral-associated cancers and disorders

296 works18,163 citations

What are the most-cited papers on Xilio Therapeutics (United States)?

ScholarIQmost cited works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate

New England Journal of Medicine. 20104,513 Citations

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

Mario E. Lacouture, John C. Morris, Donald P. Lawrence, Antoinette R. Tan, Thomas Olencki, Geoffrey I. Shapiro, Bruce J. Dezube, Jay A. Berzofsky, Frank J. Hsu, Joan Guitart

Cancer Immunology Immunotherapy. 2015151 CitationsOPEN ACCESS

How much of the research on Xilio Therapeutics (United States) is open access?

ScholarIQopen access share

50%OPEN ACCESS

Gold

Green

50%

Hybrid

Bronze

Closed

50%